Xiao Kangwen, Yang Kuangying, Hirbe Angela C
Division of Oncology, Department of Internal Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
Cancers (Basel). 2025 Jan 8;17(2):180. doi: 10.3390/cancers17020180.
Malignant peripheral nerve sheath tumors (MPNSTs) are rare but aggressive malignancies with a low 5-year survival rate despite current treatments. MPNSTs frequently harbor mutations in key genes such as , , , and PRC2 components ( or ) across different disease stages. With the rapid advancement of high-throughput sequencing technologies, the molecular characteristics driving MPNST development are becoming clearer. This review summarizes recent sequencing studies on peripheral nerve sheath tumors, including plexiform neurofibromas (PNs), atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP), and MPNSTs, highlighting key mutation events in tumor progression from the perspectives of epigenetics, transcriptomics, genomics, proteomics, and metabolomics. We also discuss the therapeutic implications of these genomic findings, focusing on preclinical and clinical trials targeting these alterations. Finally, we conclude that overcoming tumor resistance through combined targeted therapies and personalized treatments based on the molecular characteristics of MPNSTs will be a key direction for future treatment strategies.
恶性外周神经鞘瘤(MPNSTs)虽然罕见,但具有侵袭性,尽管有当前的治疗方法,其5年生存率仍很低。MPNSTs在不同疾病阶段经常在关键基因如 、 、 和PRC2组分( 或 )中存在突变。随着高通量测序技术的快速发展,驱动MPNSTs发生发展的分子特征正变得越来越清晰。本综述总结了近期关于外周神经鞘瘤的测序研究,包括丛状神经纤维瘤(PNs)、生物学潜能不确定的非典型神经纤维瘤性肿瘤(ANNUBP)和MPNSTs,从表观遗传学、转录组学、基因组学、蛋白质组学和代谢组学的角度突出肿瘤进展中的关键突变事件。我们还讨论了这些基因组学发现的治疗意义,重点关注针对这些改变的临床前和临床试验。最后,我们得出结论,基于MPNSTs的分子特征通过联合靶向治疗和个性化治疗来克服肿瘤耐药性将是未来治疗策略的关键方向。